Assessment of new technologies for cervical cancer screening

The Lancet Oncology

Volumn 9, Issue 10, 2008, Pages 910-911

  Villa, Luisa Lina ^a  

^a HOSPITAL ALEMÃO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; MOLECULAR MARKER; VIRUS DNA; WART VIRUS VACCINE;

CANCER INVASION; CANCER MORTALITY; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLPOSCOPY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LETTER; PAPANICOLAOU TEST; PATIENT MONITORING; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; UTERINE CERVIX CANCER; VACCINATION; VIRUS DETECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION; GENES, P16; GENETIC MARKERS; HUMANS; MASS SCREENING; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 52749098448     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70238-9     Document Type: Letter

References (13)

1. Bosch F.X., and de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 31 (2003) 3-13
2. Cuzick J., Mayrand M.H., Ronco G., Snijders P., and Wardle J. Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 suppl 3 (2006) 90-97
3. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101
4. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
5. Bulkmans N.W., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
6. International Agency for Research on Cancer (IARC). IARC handbook of cancer prevention. Volume 10. Cervical cancer screening (2005), IARC Press, Lyon, France
7. Qiao Y.-L., Sellors J.W., Eder P.S., et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural china. Lancet Oncol 9 (2008) 929-936
8. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26 suppl 1 (2008) A16-A23
9. Pagliusi S.R., Dillner J., Pawlita M., et al. Chapter 23: International standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 suppl 3 (2006) 193-200
10. Wentzensen N., Bergeron C., Cas F., et al. Triage of women with ASCUS and LSIL cytology: use of qualitative assessment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia. Cancer 111 (2007) 58-66
11. Horn L.C., Reichert A., Oster A., et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 32 (2008) 502-512
12. Carozzi F., Confortini M., Dalla Palma P., et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9 (2008) 937-945
13. Mao C., Balasubramanian A., Yu M., et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer 120 (2007) 2435-2438